Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch
This article was originally published in The Tan Sheet
Executive Summary
The degree of difficulty is tremendous for the first novel switch FDA approves, but it would provide a template others can follow. FDA’s interest in fostering innovative OTC switches could work in favor of proposals to make currently Rx ingredients indicated for a chronic condition available nonprescription.
You may also be interested in...
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors with a likely price of $15bn to $17bn, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.